LifeSci Continuum with Bill Schick – Details, episodes & analysis

You can’t outsource judgment, but you don’t have to do it alone. If you’re navigating go-to-market decisions in a regulated space, work with Bill through MESH as your fractional CMO.

Talk with Bill at MESH. https://meshagency.com/about-bill-schick/ 

About this episode: Early-stage medtech founders often treat regulatory strategy as a checklist item. That mistake can cost years, capital, and credibility. In this episode, I sit down with Thomas Moore, founder of PTL Solutions, to understand why regulatory strategy is actually a business roadmap and how founders can engage with it intelligently without outsourcing their judgment.

Follow Thomas: https://www.linkedin.com/in/thomas-moore-phd-40016753/
PTL Solutions: ptl-solutions.com

00:00 Defining Regulatory Strategy 
01:13 Thomas Moore Background 
02:23 Why Regulatory Strategy Is a Core Business Tool
05:41 The Problem With Checkbox Regulatory Thinking
08:49 When Regulatory Consultants Miss the Mark
10:58 Why Founders Must Stay Engaged in Regulatory Strategy
12:26 What Investors Look for in Regulatory Planning
14:25 Can Founders Build Their Own Regulatory Strategy
16:14 Where MedTech Teams Get Stuck
21:18 The Must Have Elements of a Strong Regulatory Strategy
25:56 Why Regulatory Strategy Is Not a Linear Process

Regulatory strategy is often framed as a compliance hurdle — something to outsource, check off, and move past. But as Thomas Moore, PhD explains, that mindset quietly introduces risk across the entire business.

With over two decades in medical device development, Thomas has seen what happens when founders receive a beautifully written regulatory document they can’t defend, explain, or adapt. In this conversation, he reframes regulatory strategy as a living roadmap — one that connects product design, clinical evidence, quality systems, investor confidence, and FDA credibility.

This episode is especially relevant for early-stage medtech founders navigating limited budgets, compressed timelines, and high stakes. Thomas shares why founders don’t need to do everything themselves — but why they can’t afford to be hands-off either. From pre-subs to predicate strategy to “spinning plates” across functions, this conversation gives founders language, structure, and confidence to engage regulators and consultants from a position of clarity.

If you’re building a regulated product and trying to move fast without stepping on landmines, this episode will help you think more clearly about where regulatory fits — and why it’s inseparable from business strategy.

🎧 Subscribe to LifeSci Continuum for founder-level conversations on commercialization, regulation, and building durable life-science companies. https://meshagency.com/about-bill-schick/

#MedTechFounders #RegulatoryStrategy #LifeSciences

Need investor traction now? Bring in a fractional CMO  to package your story, de-risk your milestones, and turn Tim’s engineering plan into an investable go-to-market narrative. Let’s align tech, timeline, and TAM. Book a strategy call with Bill. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Founder-friendly, investor-real talk. In his second visit to LSC, Tim Looney (Northeast Biomedical) explains how to turn prototypes into investor-ready products: DHF done right, phased engineering plans, avoiding “jam it through” FDA myths, and picking the right money. https://www.linkedin.com/in/tlooney/ 

00:00 Why do MedTech founders get stuck after early traction
03:15 What do investors actually want to see before funding
07:10 Why does skipping process slow FDA and fundraising
11:45 What documentation really matters for MedTech devices
16:40 How should founders think about de risking early
21:30 What makes a MedTech product truly investor ready

Investors aren’t funding your cool device—they’re underwriting your ability to de-risk it. In this episode, Tim Looney (President & CEO, Northeast Biomedical) returns, breaking down the investor lens for med-tech: show a credible timeline, a traceable design history file, and a stage-gated plan that prevents “surprise” testing at the eleventh hour.

We dig into DHF essentials, how to avoid endless prototyping, and why “let the FDA tell us what’s missing” is the slowest, riskiest strategy. Tim shares a standout success—an EU class III clearance in two weeks thanks to a meticulous dossier—and a cautionary tale where a buyer inherited gaps and had to backfill under FDA scrutiny.

We also talk capital: why the color of money matters, how to spot investors who add operational value, and the signaling power of ISO 13485 systems, external advisors, and documented learnings.

If you’re preparing for investors—or realizing you should have prepared earlier—connect with Bill.  Translate conviction into execution-ready roadmaps and pressure-test investor fit before urgency takes over. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ 

#MedTech #RegulatoryStrategy #InvestorReadiness

Partner sprawl stalling progress? A Fractional CMO prioritizes what moves revenue now. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ 

Connect with Greg Lange
https://www.linkedin.com/in/greg-lange-70bab04/

Early-stage medtech moves faster with the right partners. Greg Lange (Symbex) shares how to de-risk early, pick partners you can trust, and keep product + commercialization in lockstep. We cover founder archetypes, when to bring in reg/reimbursement, and the operating cadence that avoids “beautiful dead ends.”

00:00 – Who’s Greg & what Symbex does — design + commercialization under one roof
03:00 – Why partnerships matter — big-co vs startup dynamics; treat partners like partners
08:30 – The Maine case — MVP first, then V2; commercialization before “perfect”
13:30 – Founder archetypes — clinician, engineer, entrepreneur; typical misses and how to cover them
20:00 – When to bring in experts — reg, reimbursement, competitive scan; sprint without blinders
27:30 – Partner-first strategy — recruiting talent & capital by selling the vision early
33:00 – How to choose partners — trust signals, communication, no-surprises rule, say-no credibility
40:00 – Requirements & communication — MV-requirements, cadence, shared dashboards
46:00 – Budget & burn — share constraints, co-scope the work, optimize for speed-to-learning
50:00 – Three practical tips — align on mission, quarter-by-quarter deliverables, treat partners like key hires

Founder Field Manual: Three Moves That Save You Months

1) Start With the Story, Not the Spec.
 Before you sprint into building, write the one-page vision that explains why this exists, who it’s for, and how it wins. Share it with three people who would buy, use, or fund it and ask, “What’s missing?” This gives partners a north star, helps you say no to shiny objects, and turns early collaborators into advocates—because they can see where you’re going and how they fit.

2) De-Risk in Days, Not Quarters.
 Run a “week-one gauntlet”: a quick regulatory path read, a reimbursement/payor sanity check, and a 10-call voice-of-customer sprint. You’re not seeking perfection—just red-flag hunting. If a pathway, payment, or workflow blocker pops, pivot your scope now (MVP to masterpiece). This keeps burn pointed at validation instead of vanity, and it arms you with credible evidence when you talk to investors.

3) Choose Partners Like Co-Founders.
 Don’t outsource and hope—co-build and verify. Use a minimum viable requirements doc (one page is fine) and a no-surprises cadence (weekly 30-min sync + transparent task board). Favor partners who push back with alternatives (“no, and here’s the path”) over order-takers. Share your constraints—including budget—so they can design scope that actually ships. Trust, speed, and clear accountability beat rock-star resumes every time.
Founder energy is real—but so are bottlenecks. Greg Lange, President & CEO at Symbex, breaks down how early-stage teams can use partnerships to de-risk, shorten timelines, and build products the market will actually buy. We cover founder archetypes (clinician, engineer, entrepreneur), when to bring in regulatory/reimbursement, what a “good partner” looks like, and why sharing your budget is a trust signal—not a weakness.

#MedTech #Partnerships #Startup

Stuck in gridlock? Learn how a Fractional CMO can transform misalignment into momentum. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Connect with Bill: https://www.linkedin.com/in/founderandcdo/

Connect with Kata: https://www.linkedin.com/in/katalinszegner/ 

Biotech product leader Katalin “Kata” Szegner shares how to replace meeting chaos with structure: silent ideation, equal airtime, clear decision ownership, and customer-centric differentiation. We cover ending gridlock, aligning R&D with commercial, and making workshops produce real decisions—not more meetings.

00:00:00 Intro
00:01:57 Meet Kata, Teacher to Project Manager in Biotech
00:02:56 Teaching skills that supercharge product teams
00:08:12 Where misalignment starts (R&D vs. commercial)
00:10:58 Founders vs Customers, Ambition vs Traction, Growth vs. Compliance
00:16:32 Equal voices: silent ideation, dot voting, decision roles
00:26:12 Case: 18-month stall solved in hours by surfacing hidden insight
00:36:32 Workshop setup: boundaries, objectives, timeboxing, decision maker present
00:40:00 How to Set Boundaries
00:42:22 Visual frameworks that unlock clarity (Hot Air Balloon, etc.)
00:46:42 Foundation sprint & customer-centric differentiation
00:50:00 Marketing early: jobs-to-be-done and VOC as strategy, not afterthought
00:52:12 Wrap: courage, cadence, and the value of a neutral facilitator

Today’s guest, Katalin “Kata” Szegner, moved from the biology classroom to leading complex biotech products—and brought the secret with her: it’s not “clarity first,” it’s connection first. Kata shows how misalignment takes hold (founders’ vision vs. feasibility, R&D rigor vs. commercial urgency) and how to replace it with lightweight structure.

We unpack silent ideation to hear the quiet 80%, dot voting to separate ideas from egos, and clear decision ownership so meetings end in movement. Kata shares a vivid example where a team spun for 18 months—until a structured session surfaced the missing technical truth and unlocked a fix in hours.

You’ll get a simple toolkit for workshops that work: set boundaries (phones down, time blocked), publish the objective, assign the decider, and use visual frameworks (e.g., Hot Air Balloon) to make complex tradeoffs tangible. We close on customer-centric differentiation and why marketing must be present from phase zero—not as an afterthought once the science is “done.”

From Gridlock to Go: 3 Alignment Fixes Pros Miss

Equalize the room with silent ideation.
 Kick off key discussions heads-down: 60–120 seconds of quiet writing on cards or stickies before anyone speaks. Then de-dupe, group, and dot-vote. This prevents “first-voice contamination,” surfaces the 80% who rarely talk, and gives you a ranked input set to work from.

Put a decider in the room—explicitly.
 Name the decision-maker up front and confirm their attendance for the full session. Timebox each segment, finish with a single documented decision, owner, and next step. Set simple guardrails (no laptops/phones, full-day focus) so the group can actually decide, not just discuss.

Do the prework to remove surprises.
 Before the workshop, interview stakeholders, map who must be present (and influential absences), list known assumptions, and define success criteria. Bring 1–2 visual frameworks (e.g., Hot-Air Balloon) and a strawman/prototype to test the highest-risk assumption first. This turns the session into validation, not discovery.

Continue your founder’s journey with another episode: https://www.youtube.com/playlist?list=PLibD2fYYaAIISuFLmIXfzrh9_QgB9E2u8

#Biotech #ProductManagement #MedTech

Work with Bill: https://meshagency.com/lets-connect/

- Aaron Joseph https://www.linkedin.com/in/ajosephprofile/
- Russ Singleton https://www.linkedin.com/in/russellsingleton/ 

Here’s the link to their blog series: https://www.mpo-mag.com/author/russell-m-singletonrodmaneditors-mpo-com/

00:00 Introduction and guest bios (Aaron Joseph & Russ Singleton)
01:40 Backgrounds in medtech, compliance, and product development
03:40 What is Phase Zero in medical device development?
05:30 Why skipping Phase Zero leads to compliance & product failures
07:00 The physician-inventor dilemma: “I am my own customer”
10:30 Early adopters vs. mainstream market realities
13:00 Phase Zero on steroids: knowledge-building, risk reduction, and planning
19:00 Success through feasibility checks, fail-fast pivots, and market validation
25:00 Jobs-to-Be-Done, customer discovery, and avoiding founder bias
41:00 Practical advice for clinicians and teams starting innovation journeys
50:30 Final thoughts: passion, customer focus, and long-term impact

Medtech veterans and co-authors/thought leaders Aaron Joseph (Sunstone Pilot) and Russ Singleton unpack “phase zero on steroids”—the disciplined, pre-development work that de-risks science, validates real jobs-to-be-done, and sets your regulatory and reimbursement strategy before you write a line of code. Expect war stories, practical frameworks, and the permission to cancel projects early (that’s a win).

Most early-stage device teams rush into development and end up paying for it in rework, delays, or regulatory dead ends. In this episode, I chat with Aaron Joseph—principal consultant at Sunstone Pilot—and Russ Singleton—results-driven medtech executive and company builder. Aaron and Russ show you how to run Phase Zero on Steroids.

Three Tactics to Make Your Phase 0 Worthwhile
Russ and Aaron have three key takeaways for your med-tech journey pre-development, all with the promise of reducing headaches when executed properly.

Front-Load Truth, Not Features.
Begin Phase Zero by naming the job-to-be-done in one plain sentence and testing it with a representative set of users—not just top-5% surgeons. Pair a market-ear with a technology-ear in every interview to capture both desirability and feasibility. Write down kill criteria (technical, clinical, regulatory, economic) you’ll honor. If you hit them, pivot or stop. Canceling early is a success that preserves runway.

Make Science a Workstream with Exit Gates.
 Treat unknowns like experiments: define the question, the method, the success threshold, and the next decision. Time-box these studies and document what you learn so results flow directly into design inputs. In parallel, map regulatory strategy (e.g., 510(k) vs PMA), evidence requirements (clinical/usability/electrical safety/sterilization), and reimbursement hypotheses. Often the fastest market path is a tight v1.0 with limited indications that establishes a regulatory baseline.
Design for Adoption Across Four Buyers.

 You’re not just convincing a clinician—you’re convincing a system. Quantify switching costs and plan proof that speaks to (1) the user, (2) the hospital/economic buyer, (3) the payer/reimbursement gate, and (4) internal champions. Build your go-to-market around early centers that match your first winning application, then expand indications. Keep Phase Zero lean but funded: small, passionate core team; targeted outside experts; a 5-page plan that a VC—or your own GM—can say yes to.

Want help turning messy early insights into a crisp strategy, message, and launch plan? Bring in a Fractional CMO.  https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

 #MedTech #MedicalDevices #healthcareinnovation

Contact Bill: https://meshagency.com/lets-connect/

Follow Jack O’Callaghan - https://www.linkedin.com/in/jack-o-callaghan-5672636/ 

Founders don’t fail for lack of ideas—they fail for ignoring payers, regulators, and real user needs. Today I sit down with Jack O’Callaghan (Director, Business Development, Northeast Biomedical) about this very challenge. Jack explains why “build it and they will come” collapses in medtech. We get practical about payer and regulatory realities, user-needs documents, TAM fantasies, voice-of-customer, KOL strategies, and why v1.0 is never the finish line.

00:00 Why the system won’t say “yes” by default
01:27 Jack’s path: pharma → devices → engineering services
03:08 What Northeast Biomedical actually builds
04:20 Examples: reagent processor (goat blood for lateral flow), vision-guided robots, drug-delivery catheters
05:10 Where founders underestimate the journey
08:33 Reimbursement reality: enteral feeding example
12:11 You don’t sell to a person; you sell into a system
17:00 Medicine as art: implications for product design
22:56 TAM delusions and setting reachable targets
26:09 DoD “I just need to find the right person” myth
31:00 Time, bandwidth, and the cost of learning everything yourself
36:02 Prototypes, investors, and exit clarity
41:03 “I just need a distributor” (no, you don’t)
43:07 Start with user needs (engineering + commercial)
45:14 Garage prototypes and the laws of physics
47:22 Admit what you don’t know—then staff it

Three Moves That Shorten the Road to Adoption
Be realistic and think about the entire product journey. Most founders pitch a giant TAM and assume clinicians will pull the product through. Replace that with a real adoption plan. Define the serviceable market you can actually reach in the first 12–24 months, by site type and procedure volume. Map the buying center for each site: the clinical champion, the economic buyer, supply chain, biomed, and IT. Tie your value to what each of them cares about. If your claim is time saved, translate it to minutes per case and the OR cost per minute. If you reduce complications, translate it to fewer readmissions and avoid penalties. Engage payers early to confirm coding, coverage, and payment so the business case survives first contact with reality.

Admit what you don’t know and hire it early. Speed comes from admitting what you do not know and buying the right help early. Before you touch CAD again, lock a one-page user needs document and a preliminary regulatory and reimbursement path. Do a quick freedom-to-operate check. In parallel, bring in fractional experts for regulatory, quality, reimbursement, clinical affairs, and product marketing. Their fees are small compared with the cost of delay or a redesign that shows up after your first animal lab. A class II pathway can reach into the tens of millions and beyond; every month you shave by parallelizing workstreams and avoiding rework is real money and earlier evidence.

Plan to learn fast rather than launch perfect. Treat version 1 as the instrument you use to collect voice-of-customer and usability data that informs version 2 and 3. Schedule bench, cadaver, or animal sessions and capture structured feedback. Build a small KOL council and put them on a cadence. Document changes, train on the procedure, and collect outcomes that quantify your promise in terms the system buys: OR minutes avoided, length of stay reduced, fewer transfers, fewer reoperations. Line those metrics up with your coding and payment story so clinical and financial value show up in the same frame.

If your deck still shows a massive TAM but you lack a sequenced GTM, bring in a fractional CMO to convert user needs and payer logic into a market-access plan that actually moves revenue: https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

#MedTech #MedicalDevices #Mark

Connect with Bill on LinkedIn: https://www.linkedin.com/in/founderandcdo/

Discover how an on-demand Fractional CMO can sharpen your story and accelerate growth—visit https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Follow Elizabeth: https://www.linkedin.com/in/elizabethnoellumpkin/ 

00:00 Intro
02:30 Miscommunication in Medicine
06:40 Founders Miscommunication
11:35 Assumptions in Language
14:25 Identifying Your Audience
16:40 Communicating Painpoints & Needs
20:32 Credentialing
23:05 Founders Communicating to Customer
31:00 Methods for Sharing Ideas with your Founder
35:30 Trade Journal Ads
37:00 Problem vs Product
40:52 Avoiding Revolutionary Language
41:32 Advice for Founders

Medicine brims with life-saving innovation, yet audiences still tune out because the language feels alien. Today I sit down with Noel as she outlines a three-step playbook for breaking that cycle. First she shows how to pinpoint exactly who you are talking to and strip away insider shorthand that sabotages clarity. Next she demonstrates the power of storytelling—why a short patient vignette sticks long after a bullet list of specs. Finally she maps features to stakeholders’ true pain points, from clinicians starved for time to hospital CFOs bleeding cash on readmissions. 

The result is messaging that earns trust, overcomes change resistance, and moves products off the brochure page and into everyday practice.

With that in mind, here are some recommendations to better connect with your audience. 

Name the Listener, Tell the Story, Pinpoint the Pain

Start every project by writing a single sentence that defines exactly who you are talking to. A sentence like “We help over-worked oncology nurses reduce charting time” forces you to picture a real person, not a demographic blur. Once that sentence is on paper, read every headline, slide, and web page aloud using the words your audience would use in a hallway conversation. Terms that sail through an R-and-D meeting often stall when the same words land in a clinic lobby. If a phrase raises eyebrows or needs a footnote, swap it for something plainer before it leaves your desk.

Next, turn your glossary into a library of short stories. Replace abstract benefits with moments your audience can feel. “Reduces post-op hypothermia” is a statistic; “Your patient wakes up warm instead of shivering” is a scene everyone remembers. Collect these scenes in a living archive so your sales deck, social posts, and regulatory summaries draw from the same human moments. Familiar stories travel farther than flawless jargon, and they build the trust that complex data alone rarely earns.
Finally, translate each feature into a tangible pain point. Show how shaving five minutes off an intubation saves two operating-room turnovers a day, or how a single avoided readmission keeps thirty thousand dollars in the hospital’s budget. When you frame benefits in time, money, or quality metrics that already keep stakeholders up at night, your pitch stops feeling like a nice-to-have and starts reading like an urgent line item.

#LifeSciences #HealthcareInnovation #ProductMarketing

In this episode of LifeSci Continuum, I sit down with Shreya Divatia. Shreya has spent a decade rescuing med-tech programs from hidden failure points and turning “it works in the lab” into “it works on a 102-year-old patient with spotty Wi-Fi.” 

Learn how I can help you buid a bridge between your business strategy and real growth as a Fractional Chief Marketing Officer.  https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Shreya Divatia https://www.linkedin.com/in/shreya-divatia/

Timestamps:
00:00 Intro
01:30 Shreya’s Story & Experience
03:28 Shreya’s Unique Strength
04:13 Founder’s Blindspots
05:14 Wearable Med Device Case Study
08:50 Blindspots
13:17 Analysis of Wearable Med Device Case Study 
15:34 Usablity & Consumer Assumptions
18:14 Case Study Solution
19:43 Learning from Failure
22:25 How to Identify the Right Target Audience
24:10 Voice of the Customer
25:00 The Value of Feedback
29:00 3 Tips for Product Marketing
33:42 Advice for Younger Self

She walks us through an ambitious but bumpy attempt to graft a consumer wearable onto a hospital software backbone—a mash-up that looked perfect on paper until Day 3, when every sensor declared itself “disconnected.” 

Shreya unpacks why regulatory clearance is only the starting line, how to spot workflow landmines before nurses do, and the mind-shift founders need when hardware, software, and human factors collide inside real wards.

Three Overlooked Checks That Decide Whether Your Hospital Pilot Lives or Dies

Many founders race from first prototype to regulatory green light and assume the toughest hurdles are behind them. In reality the true test begins when a night-shift nurse clips your sensor to a patient and expects flawless data while juggling alarms, charting, and a shaky Wi-Fi network. 

The steps that most teams skip are not glamorous pieces of science or elegant code. They are blunt reality checks that expose whether your device can survive the messy, unpredictable world of a hospital ward. Ignoring them does not merely delay a launch. It erodes staff trust, drains investor patience, and risks patient safety.

Running shadow trials on the actual unit rather than only in the engineering lab is your first safeguard. Hospital corridors bounce Bluetooth signals off metal carts, routers drop packets every time someone microwaves lunch, and vitals rounds happen when your entire dev team is asleep. A single overnight trial uncovers battery-drain patterns, latency spikes, and pairing failures that weeks of office testing never reveal. 

The second safeguard is mapping every quiet stakeholder by role and watching how they naturally interact with your prototype. Certified nursing assistants reposition patients and tug on cords you labeled “do-not-pull.” Biomedical engineers dismantle housings for their mandatory weekly cleaning routine and expose boards you never coated for disinfectant. 

Housekeeping staff unplug your access point because they need the outlet for a floor polisher. These improvised work-arounds are early warning signals. What breaks under their normal workflow will become the reason nurses refuse to wear your pager on their belts six months later, even if the chief medical officer loved your demo.

Finally, teams must separate “regulatory safe” from “workflow safe” in their timeline and budget. Passing IEC and FDA tests confirms electrical safety and basic performance, but it says nothing about whether the device keeps streaming when bandwidth drops, whether a clinician mistakes an antenna for a convenient handle, or whether alerts merge seamlessly into the hospital’s existing middleware. 

 #HealthcareInnovation #ProductMarketing #PatientSafety

In this episode of LifeSci Continuum, I sit down with Pete Tortorell, GM/Managing Director of Omni International (now Revvity). 

Timestamps:
00:00 Intro
01:24 Pete’s Story
02:07 COVID19 Case Study
07:20 Good Marketing is Hard to Find
12:00 Working with MESH Interactive
13:32 Lead Generation
14:50 Measuring KPIs
17:20 The Value of a FCMO
24:30 Marketing Education
26:05 Marketing Competition
28:45 Traditional Marketing is Dead
31:15 Founder & CEO Advice

When 2020 erased half of Omni International’s revenue in a single month, Pete didn’t slash headcount—he rebuilt the business. 

Join me as Pete traces Omni’s journey from a stand-alone sample-prep brand to a Revvity business unit that still owns its P&L and customer relationships. He recounts the 2020 free-fall when labs closed worldwide, the rapid collaboration with Georgia Tech that repositioned saliva testing, and the acquisition turbulence that followed. 

Pete explains why he skipped agency “textbook” pitches and chose a fractional CMO who could challenge assumptions, and built a repeatable framework that any mid-market life-science company can copy to generate demand without hiring a dozen specialists.

Do you think your marketing investment is going to waste? Learn why Founders are turning to FCMOs: https://meshagency.com/for-founders/

Three Overlooked Fixes That Turn Marketing Spend Into Pipeline Growth
Most early-stage companies assume a bigger marketing budget will automatically translate into qualified leads, yet the same dollars often vanish into tactics that look busy but move no revenue. The root causes usually hide in three places: unexamined spending, rigid staffing models, and content that talks instead of proves.

First, every life-science or med-device founder needs a single pane of glass for company health, marketing traction, and customer-service pulse. 

First, hook your source-of-truth systems (ERP, CRM, and ticketing) to a lightweight BI tool—don’t custom-code; Zapier or native connectors will do. Second, agree on three to five metrics per area before you design anything; if it doesn’t guide a decision, kill it. Third, set automated alerts at the “uh-oh” thresholds so you react in hours, not quarters—think churn spike, lead-to-SQL drop, or NPS dip. Do that, and you’ve got a living cockpit that keeps the science moving and the money people smiling.

Second, think of senior marketing expertise as cloud infrastructure: rent it when you need it, scale it back when you do not, and keep permanent headcount focused on the science and customer support your brand is known for. Founders who insist on a full-time director before product-market fit end up paying executive salaries for work that could be handled fractionally (and at a fraction of the cost). A flexible model also brings in fresh perspective every quarter and prevents your message from calcifying around last year's tactics.

Finally, replace generic product copy with application stories authored by the scientists who actually use your products. Prospects trust peers who can say, “This homogenizer cut my sample-prep time by forty percent,” far more than they trust brochure language about “innovative design.” When real users explain the before and after of throughput, reproducibility, and budget impact, conversion rates climb and sales conversations start closer to the finish line. Marketing shifts from a push activity to proof that the tool already delivers in labs just like theirs.

Learn how I can help you grow your business as a Fractional Chief Marketing Officer. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

In this episode of LifeSci Continuum, I sit down with Laurel Nelson (Founder, InnovexDx), who breaks down how diagnostics and life-science start-ups can actually commercialize when cash is tight and timelines keep slipping. 

Learn how I can help you grow your business as a Fractional Chief Marketing Officer. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Timestamps:
00:00 Intro
01:10 Laurel Nelson’s Career
02:50 Launching a Product with a Limited Budget
06:01 Common Founder Challenges
14:22 Founder Scientists vs Marketing
16:00 How to Build Credibility with Investors
21:15 Preparing a Good Idea for Commercialization
26:01 Phase Gate
28:26 How to Find Market Data
32:14 Market Access
35:25 Being Transparent with Investors
39:50 3 Tips for Founders
41:04 Wisdom for Younger Self

She explains why constant “lab tinkering” kills launch velocity, how a lightweight phase-gate process forces objective kill/keep decisions, and where founders routinely underrate market-access spending. 

We also dig into her favorite “pressure-tests” for product-market fit, why external verification must precede scale, and how to recut the business case at every milestone so investors stay onside.

Three Commercial “Gotchas” That Sink More Lab-Startup Launches Than the Science Itself

Most first-time founders pour their energy into perfecting assay sensitivity or edge-case workflow hacks, yet overlook the far less glamorous forces that actually determine market uptake— reimbursement math, risk-gated execution, and supply-chain resilience. Laurel Nelson’s work with diagnostics start-ups shows the same three blind spots cropping up again and again, each capable of halving a valuation before anyone discovers an analytical bug.

Start with reimbursement, not with the prototype. The CPT or PLA code you intend to bill against—along with its evidence requirements and likely payment rate—quietly dictates half of your design envelope: sample-to-answer time, staff touch points, throughput thresholds, even consumable cost ceilings. Founders who “figure out coding later” end up redesigning hardware to hit margin, or worse, they head to market trapped under a price cap that investors immediately factor into a down-round.

Next, enforce micro phase-gates—even if that’s nothing more than three Google slides and a Slack channel. Moving an idea through quick feasibility, alpha verification, and an external beta test surfaces killer assumptions while the fixes are still cheap. These lightweight gates catch the moment a clinician says, “Great data, but my lab would never change this workflow,” before you’ve ordered production molds or spun up a $200 k validation study. They also give boards the proof points they need to keep financing flowing without funding every shiny R&D tangent.

Finally, lock dual-vendor coverage for every critical consumable as soon as verification passes. A single polymerase lot that fails QC can stall trials for months, derailing a Series A timeline and torching your credibility with early adopters. Qualifying at least two suppliers—complete with incoming QC specs—turns supply hiccups into routine purchase-order swaps and lets you scale when that first major hospital system says yes.

None of these moves are exciting science, and that’s the point. They remove the non-scientific landmines that so often explode after launch, allowing the real innovation to speak for itself—and to get paid.

#Commercialization #MarketAccess #ClinicalUtility #BootstrappedLaunch #InvestorReadiness #ReimbursementStrategy #LifeScienceStartups